Why Weight Gain Happens During Menopause
Menopause can bring a wave of unexpected changes—weight gain being one of the most frustrating. Many women notice fat accumulating around the abdomen, even when diet and lifestyle habits have not changed. This is not a matter of willpower—it is physiology.
The driving force is hormonal. Declining oestrogen during perimenopause and menopause profoundly affects how the body stores fat and burns energy. Key changes include:
- Slower metabolism — basal metabolic rate decreases as oestrogen levels fall, meaning fewer calories are burned at rest even without changes in activity.
- Muscle loss (sarcopenia) — hormonal changes accelerate the age-related loss of muscle tissue, further reducing calorie expenditure.
- Increased visceral fat — fat redistribution shifts from hips and thighs to the abdomen, significantly increasing the risk of cardiovascular disease and type 2 diabetes.
- Stronger cravings — hormonal disruption affects appetite-regulating hormones including leptin and ghrelin, increasing cravings for sugar and high-calorie foods.
How Mounjaro Helps with Menopause Weight
Mounjaro (tirzepatide) works differently from traditional weight loss methods. Rather than simply restricting intake through willpower, it targets the hormonal regulation of appetite and metabolism directly—making it particularly relevant for menopausal weight gain.
Its dual-hormone mechanism acts on two pathways:
- GLP-1 (glucagon-like peptide-1) — slows gastric emptying, signals fullness to the brain, and reduces appetite. This directly counters the increased cravings associated with menopausal hormonal change.
- GIP (glucose-dependent insulinotropic polypeptide) — improves insulin response and fat metabolism. This is particularly relevant during menopause, when declining oestrogen contributes to increased insulin resistance.
For menopausal women, this combination of effects offers:
- Reduced cravings and emotional eating triggered by hormonal fluctuation
- Improved blood sugar stability, countering menopause-related insulin resistance
- Enhanced fat loss—particularly abdominal/visceral fat
- Better long-term weight control compared to calorie restriction alone
Expected Results: What the Data Shows
Clinical trial data for Mounjaro is compelling, though it is important to note that most major trials did not isolate menopausal women as a specific subgroup. The overall results provide a strong indication of what is achievable:
For menopausal women specifically, the metabolic benefits may translate to:
- Meaningful reduction in visceral (abdominal) fat—the type most closely linked to cardiovascular and metabolic risk
- Lower cardiovascular risk factors (blood pressure, cholesterol, blood sugar)
- Increased energy and improved mobility as body weight reduces
- Reduced burden of menopause-associated metabolic conditions including type 2 diabetes risk
Is Mounjaro Right for You?
In the UK, eligibility for Mounjaro follows NICE guidance (TA1026) and typically requires:
- BMI ≥ 30 (obesity), or
- BMI ≥ 27 with at least one weight-related health condition (e.g. type 2 diabetes, hypertension, high cholesterol, sleep apnoea)
Mounjaro is generally not suitable if you:
- Are pregnant or breastfeeding
- Have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Have a history of pancreatitis
- Have severe gastrointestinal conditions
Can You Take Mounjaro with HRT?
This is one of the most common questions from menopausal women considering Mounjaro. In most cases, the answer is yes—HRT and Mounjaro address different aspects of menopause and can be used together.
- HRT targets hormonal deficiency—replacing oestrogen (and sometimes progesterone and testosterone) to manage symptoms like hot flushes, sleep disruption, mood changes, and bone density loss.
- Mounjaro targets metabolic and weight outcomes— reducing appetite, improving insulin response, and supporting sustained weight loss.
There is no established clinical contraindication between HRT and tirzepatide. However, the interaction between medications should always be reviewed by a clinician who has full visibility of your medical history and current prescriptions. Some forms of HRT may affect appetite and weight independently, which is worth discussing with your prescriber.
Maximising Results: Lifestyle Strategy
Mounjaro works best when paired with a structured lifestyle approach. During menopause, specific strategies are particularly effective:
1. Strength Training
Resistance training is the single most effective lifestyle intervention for menopausal women on a weight loss programme. Strength training:
- Prevents and reverses muscle loss (sarcopenia) accelerated by menopause
- Boosts resting metabolic rate — more muscle means more calories burned at rest
- Improves bone density, reducing osteoporosis risk
Even 2–3 sessions per week of moderate resistance training makes a clinically meaningful difference. This does not require a gym— bodyweight exercises, resistance bands, or free weights at home are all effective.
2. Protein-Rich Diet
Prioritising protein supports muscle retention and enhances Mounjaro's satiety effect. See our Mounjaro nutrition guide for detailed dietary recommendations, including protein targets and food sources.
3. Stress Management
Chronic stress elevates cortisol, which directly promotes visceral fat accumulation—the primary site of menopause-related fat gain. Strategies such as mindfulness, adequate sleep, and moderate aerobic exercise all help manage cortisol levels and support weight loss outcomes.
Menopause does not have to mean inevitable weight gain. With a treatment like Mounjaro and a targeted lifestyle approach—strength training, adequate protein, and stress management— sustainable weight loss is achievable. The key is combining clinical support with consistent lifestyle habits, rather than relying on either alone.
Related Guides
Sources & Further Reading
This guide references the following official and authoritative sources.
- 1NHS — Menopause symptoms and treatment
NHS overview of menopausal symptoms including weight gain, metabolic changes, and evidence-based treatment options.
- 2SURMOUNT-1 trial — Tirzepatide (Mounjaro) clinical results
Phase 3 trial published in NEJM showing up to 22.5% body weight reduction with tirzepatide over 72 weeks.
- 3NICE — Tirzepatide for managing overweight and obesity (TA1026)
NICE technology appraisal on tirzepatide eligibility criteria and clinical use in the UK.
- 4British Menopause Society — Weight management in menopause
Evidence-based guidance from the BMS on the drivers of menopausal weight gain and management approaches.
- 5Mounjaro weight loss injection UK — full guide — Health Wise
Complete independent guide to Mounjaro—mechanism, clinical results, eligibility, and UK pricing.
- 6Mounjaro nutrition guide UK — Health Wise
Evidence-based nutrition advice for getting the most from Mounjaro treatment.
Frequently Asked Questions
Can menopausal women take Mounjaro in the UK?
Yes—menopausal women are eligible for Mounjaro under the standard UK criteria (BMI ≥ 30, or ≥ 27 with a related health condition). Menopause itself is not a contraindication. In fact, menopausal women are among those who may benefit most from Mounjaro's dual mechanism, which addresses both appetite and insulin response.
Why is menopause weight gain different from regular weight gain?
Menopausal weight gain is driven by hormonal changes—particularly declining oestrogen—rather than simply eating more. These changes alter fat distribution (increasing visceral/abdominal fat), slow metabolic rate, reduce muscle mass, and increase insulin resistance. This means standard calorie restriction alone is often less effective.
Can I take Mounjaro alongside HRT?
In most cases, yes. HRT and Mounjaro address different aspects of menopause: HRT targets hormonal deficiency and symptoms (hot flushes, sleep disruption), while Mounjaro supports weight and metabolic health. There is no established contraindication between the two. However, always discuss both treatments with your GP or specialist, as individual clinical circumstances vary.
Does Mounjaro specifically target abdominal fat?
Clinical trials show that Mounjaro reduces visceral (abdominal) fat as part of overall weight loss. While no medication can target fat in a single area exclusively, the metabolic improvements from Mounjaro's GIP mechanism—improved insulin sensitivity and fat metabolism—tend to have a proportionally greater effect on visceral fat stores.
How long does it take to see results on Mounjaro during menopause?
Most patients begin to notice appetite changes within the first 1–2 weeks. Meaningful weight loss typically becomes apparent from weeks 4–8, with the most significant changes occurring over 12–24 weeks as the dose is titrated upward. Clinical trial data shows progressive weight loss over 72 weeks with Mounjaro.
Are there any menopause-specific risks with Mounjaro?
No menopause-specific contraindications have been identified. Standard Mounjaro contraindications apply: history of pancreatitis, medullary thyroid cancer or MEN2 syndrome, pregnancy, and certain other conditions. Your prescribing clinician will review your full medical history before prescribing.
